What is Obatala Sciences?
Obatala Sciences is a specialized life sciences manufacturer at the forefront of human-derived hydrogels, stem cells, and functional Fat-on-a-chip models. By providing high-fidelity tools for pre-clinical drug development, the company enables researchers to gain deeper insights into complex metabolic diseases. Their product portfolio, which includes the innovative ObaCell kits and specialized biomaterials, is designed to bridge the gap between laboratory research and clinical trials. By focusing on human-centric models, Obatala Sciences aims to improve the efficacy and equity of therapeutic outcomes for patients globally, positioning itself as an essential partner for pharmaceutical and biotechnology firms seeking to optimize their drug discovery pipelines.
How much funding has Obatala Sciences raised?
Obatala Sciences has raised a total of $3.1M across 2 funding rounds:
Debt
$92K
Series A
$3M
Debt (2021): $92K with participation from PPP
Series A (2022): $3M led by Ochsner Lafayette General Healthcare Innovation Fund, Elevate Capital Fund, Hackett Robertson Tobe Group, Benson Capital Partners, and être Venture Capital
Key Investors in Obatala Sciences
Hackett Robertson Tobe Group
An independent institutional investment consulting firm and registered Investment Adviser providing customized counsel to public funds and retirement plan sponsors with a focus on sustainable and equitable solutions.
Benson Capital Partners
A New Orleans-based firm operating within the investment banking sector, providing strategic financial support to emerging growth companies.
Ochsner Lafayette General Healthcare Innovation Fund
A specialized healthcare innovation fund focused on backing transformative technologies that improve patient outcomes and clinical efficiency.
What's next for Obatala Sciences?
With the recent infusion of capital, Obatala Sciences is poised to expand its operational capacity and market reach. The strategic focus will likely center on scaling the production of its core hydrogel and stem cell technologies to meet the growing demand for more accurate pre-clinical testing platforms. Furthermore, the company is expected to deepen its research and development efforts, potentially exploring new applications for its Fat-on-a-chip models in broader therapeutic areas. As the firm continues to mature, the emphasis will remain on establishing long-term partnerships with clinical research organizations and pharmaceutical entities, ultimately driving the transition of more effective therapies from the bench to the bedside.
See full Obatala Sciences company page
